REGULATORY
After Taltz Given High Price, MHLW to Push Use of Other Psoriasis Drugs; Revision to Foreign Price Adjustment Eyed
The Ministry of Health, Labor and Welfare (MHLW) will issue a notification calling on physicians to use psoriasis medicines similar to Taltz (ixekizumab) prior to the Eli Lilly drug, which fetched a high reimbursement price due to an adjustment based…
To read the full story
Related Article
REGULATORY
- Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
February 20, 2026
- Health Minister Signals Early March Approval for iPSC Products
February 20, 2026
- Takaichi Urges Public-Private Investment Push in Drug Discovery
February 20, 2026
- Two iPSC-Derived Products Now in Line for Conditional Approval
February 20, 2026
- PM Takaichi Keeps Cabinet Intact after Lower House Vote
February 18, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





